# Century Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/century-therapeutics

- Industry: Biotechnology
- Headquarters: Philadelphia, US
- Website: www.centurytx.com
- Total disclosed funding: $410M
- Latest round: Series C (Feb 25, 2021)
- Investors on record: 14

## About

Founded in 2018 and based in Pennsylvania, US, Century Therapeutics, Inc. operates as a biotechnology company that develops induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology. In March 2020, Century Therapeutics raised USD 160 million in Series C funding led by Casdin Capital. The company has 107 employees as of April 2021.  In June 2021, Century Therapeutics, Inc. raised USD 211 million in IPO, selling 10.6 million shares at USD 20 per share on the NASDAQ. It trades on NASDAQ under the ticker symbol IPSC.

Century Therapeutics is harnessing the power of adult stem cells to develop curative cell therapy products for cancer. The company's genetically engineered, iPSC-derived iNK and iT cell products are designed to specifically target hematologic and solid tumor cancers.

The company plans to use its Series C funding to help the pre-clinical pipeline, which includes multiple iPSC-derived CAR-iT and CAR-iNK cell products. These products are designed to resist host rejection, enhance cell persistence, and allow repeat dosing to provide durable responses in all patients.

## Funding rounds

- Series C, Feb 25, 2021, $160M — OrbiMed Advisors, Versant Ventures, Marshall Wace, Qatar Investment Authority, Fidelity Investments, MDT Advisers, Casdin Capital, RA Capital Management, Octagon Capital, Leaps by Bayer, Logos Capital, Avidity Partners
- Series A, Jun 30, 2019, $250M — Versant Ventures, Bayer AG, Cellular Dynamics International, Inc.

## Investors

- Versant Ventures (https://capitalatlas.ai/funds/versant-ventures) — Series A, Series C
- Bayer AG — Series A
- Cellular Dynamics International, Inc. — Series A
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series C
- Marshall Wace (https://capitalatlas.ai/funds/marshall-wace) — Series C
- Qatar Investment Authority (https://capitalatlas.ai/funds/qatar-investment-authority) — Series C
- Fidelity Investments (https://capitalatlas.ai/funds/fidelity-investments) — Series C
- MDT Advisers — Series C
- Casdin Capital (https://capitalatlas.ai/funds/casdin-capital) — Series C
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series C
- Octagon Capital — Series C
- Leaps by Bayer (https://capitalatlas.ai/funds/leaps-by-bayer) — Series C
- Logos Capital (https://capitalatlas.ai/funds/logos-capital) — Series C
- Avidity Partners — Series C